Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas
- 4 August 2010
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 102 (2) , 317-321
Abstract
Current therapies for recurrent or progressive high-grade gliomas (HGG, WHO grade 3–4) produce a 6-month progression-free survival of only 10–25%. Migration and invasion by HGG is mediated in part by matrix metalloproteases (MMPs) which promote remodeling of the extracellular matrix. Several HIV protease inhibitors (HIVPI) decrease the expression of MMPs in astrocytes and microglia. Given these mechanisms of antitumor activity of HIVPI, we evaluated the efficacy of ritonavir/lopinavir, a combination HIVPI, in patients with progressive or recurrent HGG in an open label phase II trial. Nineteen patients were treated in this study. Patients received ritonavir/lopinavir (400 mg/100 mg) orally twice daily. All patients were treated until progression of disease or unacceptable toxicity. A complete response was seen in one patient (5%). Three patients (16%) had stable disease as the best response. Fifteen patients (79%) had progressive disease. The 6-month progression free survival (PFS6) was 11% (2 of 19 patients). Ritonavir/lopinavir was well tolerated in patients with heavily pretreated refractory HGG, and no grade 3 or 4 toxicity was seen. The activity at the dose and schedule used in this study, however, was modest and the study did not meet its efficacy endpoint.Keywords
This publication has 21 references indexed in Scilit:
- Effects of cytochrome P450 3A (CYP3A) and the drug transporters P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavirBritish Journal of Pharmacology, 2010
- New molecular targets in angiogenic vessels of glioblastoma tumoursExpert Reviews in Molecular Medicine, 2008
- Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBMNeuro-Oncology, 2008
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomasNeuro-Oncology, 2008
- HIV Protease Inhibitors Decrease VEGF/HIF-1α Expression and Angiogenesis in Glioblastoma CellsNeoplasia, 2006
- HIV Protease Inhibitors Block Akt Signaling and Radiosensitize Tumor Cells Both In vitro and In vivoCancer Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microgliaBrain, 2004
- Lopinavir/RitonavirDrugs, 2003
- Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiformeJournal of Neurosurgery, 1983